The FDA has authorized Minder, the first implantable continuous electroencephalogram monitor, offering long-term brain activity tracking for improved epilepsy management, available in the U.S.
The FDA and HHS announced plans to eliminate petroleum-based synthetic food dyes, citing potential health risks and aligning with global safety standards.
Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.
The FDA has authorized CT-132, the first prescription digital therapeutic for episodic migraine prevention, based on clinical trial data showing reduced monthly migraine days.
“Approval of an immediate-use intranasal diazepam treatment that can be given at any time—even while a child is actively seizing—in this young age group is an important advance for the epilepsy community.”